List view / Grid view

Committee for Medicinal Products for Human Use (CHMP)

 

Sandoz proposed biosimilars recommended for EU approval

25 April 2017 | By Niamh Marriott, Junior Editor

The Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions, separately recommending the approval of both Sandoz's (a Novartis division) biosimilar rituximab and biosimilar etanercept in Europe, to treat the same indications as their respective reference medicines.

AbbVie receives CHMP positive opinion for Hep C tablet combination

2 March 2017 | By Niamh Marriott, Digital Editor

The European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for Abbvie’s shorter, eight-week treatment of Viekirax (ombitasvir/paritaprevir/ritonavir tablets) + Exviera (dasabuvir tablets) as an option for previously untreated adult patients with geotype 1b chronic hepatitis C virus (HCV)…

CHMP positive opinion for Keytruda in NSCLC

27 June 2016 | By Victoria White, Digital Content Producer

The CHMP has recommended approval of Keytruda for the treatment of locally advanced or metastatic NSCLC in adults whose tumours express PD-L1...

Send this to a friend